Research ArticleArticle
Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen and Markku Kauppi for the NEO-RACo Study Group
The Journal of Rheumatology November 2019, jrheum.190139; DOI: https://doi.org/10.3899/jrheum.190139
Tia Sandström
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Vappu Rantalaiho
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Timo Yli-Kerttula
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Hannu Kautiainen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Timo Malmi
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Anna Karjalainen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Tea Uusitalo
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Heikki Julkunen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Oili Kaipiainen-Seppänen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Leena Paimela
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Kari Puolakka
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Toini Uutela
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Timo Möttönen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Pekka Hannonen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Marjatta Leirisalo-Repo
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Leena Laasonen
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Markku Kauppi
From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish. T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital. Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi. Accepted for publication November 5, 2019.
Article Information
jrheum.190139
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online June 1, 2020.
Article Versions
- Latest version (November 15, 2019 - 04:00).
- You are currently viewing a Latest version of this article (June 1, 2020 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2020 The Journal of Rheumatology
Author Information
- Tia Sandström,
- Vappu Rantalaiho,
- Timo Yli-Kerttula,
- Hannu Kautiainen,
- Timo Malmi,
- Anna Karjalainen,
- Tea Uusitalo,
- Heikki Julkunen,
- Oili Kaipiainen-Seppänen,
- Leena Paimela,
- Kari Puolakka,
- Toini Uutela,
- Timo Möttönen,
- Pekka Hannonen,
- Marjatta Leirisalo-Repo,
- Leena Laasonen and
- Markku Kauppi; for the NEO-RACo Study Group
- From the Department of Rheumatology, and the Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki; Centre for Rheumatic Diseases, Tampere University Hospital; Faculty of Medicine and Health Technology, Tampere University, Tampere; Department of Rheumatology, Satakunta Central Hospital, Rauma; Primary Health Care Unit, Kuopio University Hospital, Kuopio; Folkhälsan Research Center, Helsinki; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; Orton Orthopaedic Hospital, Helsinki; South Karelia Central Hospital, Lappeenranta; Department of Medicine, Lapland Central Hospital, Rovaniemi; School of Medicine, University of Turku, Turku; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.
This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, and the Finnish Society for Rheumatology. At baseline, an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of infliximab. Schering-Plough Finland also provided support for investigator meetings. The funders did not have any role in the study design, data collection and analysis, preparation of the manuscript, or decision to publish.
T. Sandström, MD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; V. Rantalaiho, MD, PhD, Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty of Medicine and Health Technology, Tampere University; T. Yli-Kerttula, MD, PhD, Department of Rheumatology, Satakunta Central Hospital; H. Kautiainen, BA, Primary Health Care Unit, Kuopio University Hospital, and Folkhälsan Research Center; T. Malmi, MD, Department of Medicine, Seinäjoki Central Hospital; A. Karjalainen, MD, PhD, Department of Rheumatology, Oulu University Hospital and University of Oulu; T. Uusitalo, MD, Department of Medicine, Hämeenlinna Central Hospital; H. Julkunen, MD, PhD, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; O. Kaipiainen-Seppänen, MD, PhD, Department of Medicine, Kuopio University Hospital; L. Paimela, MD, PhD, Orton Orthopaedic Hospital; K. Puolakka, MD, PhD, South Karelia Central Hospital; T. Uutela, MD, PhD, Department of Medicine, Lapland Central Hospital; T. Möttönen, MD, Professor, School of Medicine, University of Turku; P. Hannonen, MD, Professor, Department of Rheumatology, Central Hospital of Central Finland; M. Leirisalo-Repo, MD, Professor, Department of Rheumatology, Helsinki University Hospital and University of Helsinki; L. Laasonen, MD, PhD, Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki; M. Kauppi, MD, Professor, Faculty of Medicine and Health Technology, Tampere University, and Department of Rheumatology, Päijät-Häme Central Hospital.
Address correspondence to Dr. T. Sandström, Department of Rheumatology, Helsinki University Hospital, PO Box 372, 00029 HUS, Finland. E-mail: tia.sandstrom@hus.fi.
Accepted for publication November 5, 2019.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen, Markku Kauppi
The Journal of Rheumatology Nov 2019, jrheum.190139; DOI: 10.3899/jrheum.190139
Cervical Spine Involvement among Patients with Rheumatoid Arthritis Treated Actively with Treat-to-target Strategy: 10-year Results of the NEO-RACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen, Markku Kauppi
The Journal of Rheumatology Nov 2019, jrheum.190139; DOI: 10.3899/jrheum.190139